Novavax Looks To Increase Runway Through Strategic Alliance With India’s Cadila Pharma
This article was originally published in PharmAsia News
Executive Summary
A recently announced three-prong partnership with India's Cadila Pharmaceuticals should enable Novavax to pay off $22 million in convertible debt due in July and still have about one year's worth of operating cash, the vaccine maker's chief executive, Rahul Singhvi, said in an interview
You may also be interested in...
Novavax Eyes Asia Expansion As Vaccines Portfolio Progresses
The U.S. vaccines company Novavax is making inroads into Asia and developing markets with its influenza and RSV vaccines.
Novavax Eyes Asia Expansion As Vaccines Portfolio Progresses
The U.S. vaccines company Novavax is making inroads into Asia and developing markets with its influenza and RSV vaccines.
South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax
SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S